Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Talpaz

Showing results (171-180 of 264) with videos related to

Pageof 27
Sort By:
Cancer Chemotherapy and Pharmacology|April 24, 2013
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignanciesDaryl Sonnichsen, David J Dorer, Jorge Cortes, et al.
The Lancet. Haematology|September 21, 2019
Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trialAsra Ahmed, Samuel A Merrill, Fares Alsawah, et al.
Blood|June 13, 2014
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsPaul G Richardson, Rachid Baz, Michael Wang, et al.
Haematologica|April 2, 2024
<i>Erratum</i> to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopeniaSrdan Verstovsek, Ruben Mesa, Moshe Talpaz, et al.
Haematologica|September 23, 2021
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopeniaSrdan Verstovsek, Ruben Mesa, Moshe Talpaz, et al.
Hemasphere|May 10, 2021
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA TrialRuben A Mesa, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Cancer|April 5, 2002
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemiaSusan O'Brien, Moshe Talpaz, Jorge Cortes, et al.
British Journal of Haematology|May 23, 2013
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 studyNeil P Shah, Moshe Talpaz, Michael W N Deininger, et al.
Blood|August 15, 2002
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemiaHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Haematologica|October 30, 2016
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosisJohn O Mascarenhas, Moshe Talpaz, Vikas Gupta, et al.
Pageof 27

Showing results (171-180 of 264) with videos related to

Sort By:
Pageof 27
Cancer Chemotherapy and Pharmacology|April 24, 2013
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignanciesDaryl Sonnichsen, David J Dorer, Jorge Cortes, et al.
The Lancet. Haematology|September 21, 2019
Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trialAsra Ahmed, Samuel A Merrill, Fares Alsawah, et al.
Blood|June 13, 2014
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patientsPaul G Richardson, Rachid Baz, Michael Wang, et al.
Haematologica|April 2, 2024
<i>Erratum</i> to: Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopeniaSrdan Verstovsek, Ruben Mesa, Moshe Talpaz, et al.
Haematologica|September 23, 2021
Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopeniaSrdan Verstovsek, Ruben Mesa, Moshe Talpaz, et al.
Hemasphere|May 10, 2021
Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA TrialRuben A Mesa, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Cancer|April 5, 2002
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemiaSusan O'Brien, Moshe Talpaz, Jorge Cortes, et al.
British Journal of Haematology|May 23, 2013
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 studyNeil P Shah, Moshe Talpaz, Michael W N Deininger, et al.
Blood|August 15, 2002
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemiaHagop M Kantarjian, Susan O'Brien, Jorge E Cortes, et al.
Haematologica|October 30, 2016
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosisJohn O Mascarenhas, Moshe Talpaz, Vikas Gupta, et al.
Pageof 27